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Gastric cancer still represents one of the most challenging
problems for oncologists. Despite diagnostic and technologic
advances with improvement of perioperative care, gastric
carcinoma remains the fifth leading cause of death due to
cancer in Western countries. The age standardised incidence
has shown a decrease, during the first and last quinquen-
nium, from 17.42 to 15.30 per 100,000 population among
31,716 gastric cancers registered between 1957 and 1981 in
the United Kingdom (Allum et al., 1989a). There is an
apparent increase in the proportion ofproximal lesions and a
decrease in the proportion of distal antral cancers (Allum et
al., 1989a; Cady et al., 1989). For the majority of the patients
the diagnosis means a strong likelihood of death. The 5-year
survival rates were only 7% to 10% and there has been
relatively little improvement in this outlook over the past 30
years (Kern, 1989).
Before investigating the possible role of adjuvant treatment
in improving survival one should be convinced that optimal
surgery was performed. In Europe and in the United States,
50% to 60% of patients have their primary tumour resected
and approximately half of these patients are considered by
the surgeon and the histopathologist to have had curative
resection. Nevertheless, up to two third of the patients, in
this so-called curative resection group, undergo relapse and
die due to locoregional failure (87%).
The extent of locoregional gastric cancer spread is un-
predictable, since the lymphatic drainage of the stomach
widely overlaps. Accordingly, extended lymphadenectomy
has been investigated during the last few years. In Japan,
retrospective studies suggest that improved survival is possi-
ble when extended lymphadenectomy is added to gastric
resection. However, most of the cures were obtained in
patients whose disease had not passed through the serosa.
For patients with infiltration of the surrounding tissues, only
17% will survive over 5 years (Milewski & Bancewiz, 1989), a
figure also observed after less radical surgery (Fielding et al.,
1980). American and European surgeons rarely add extended
lymphadenectomy to resection for gastric cancer. This prac-
tice is also largely based on retrospective clinical trial reviews
that have shown the inability of lymphatic dissection to
improve survival. The question of optimal surgery needs to
be solved urgently in order to be able to interpret properly
the results of adjuvant trials.
Because the vast majority of patients with gastric cancer
have local intra-abdominal recurrence (Gunderson et al.,
1982), treatments focused on controlling local tumour burden
might be of major interest.
Radiation therapy is only minimaly effective in patients
with advanced gastric cancer (Balikdjian et al., 1980). In
patients with locally unresectable gastric cancer, 5-FU during
the first days of radiotherapy produced a significant increase
in the mean survival when compared to radiation alone
(Moertel et al., 1969). Whether radiation therapy offers any
potential efficacy as an adjuvant treatment in gastric cancer
has never been adequately tested. Available data indicate that
radiation therapy is well tolerated and that long survivals
may be observed (Bleiberg et al., 1989; Moertel et al., 1984).
Intraoperative radiotherapy has been initiated in Japan. In
non randomised series, patients received intraoperative
radiotherapy at dosages ranging from 2800 to 4000 cGy. No
benefit in survival was apparent for the entire patient popula-
tion. A benefit in survival was suggested only for a subgroup
of patients with stage IV disease (Abe & Takahashi, 1981).
There is a need for clinical trials designed to confirm or
deny the possibility of creating radiotherapeutic regimens of
low toxicity and high therapeutic benefit.
Disease spread on the peritoneal surface is another major
site of failure after surgery. Intraperitoneal chemotherapy has
been used with limited success for at least 30 years. The
pharmacokinetics of chemotherapy is well documented (Ded-
rick et al., 1978), and the rational basis for the use of
immediate postoperative intraperitoneal chemotherapy is
convincing (Cunliffe & Sugarbaker, 1989), but no randomised
controlled studies have yet been initiated.
Chemotherapy is aimed at eradicating the malignant cells
which have disseminated before or at the time of surgery. It
is supposed that those treatments which are active in
advanced disease would also be active at an earlier stage of
the disease. 5-Fluorouracil (5FU,F) doxorubicin (A), mito-
mycin C (MMC), etoposide (E), the nitrosoureas semustine
(MeCCNU) and carmustine and cisplatin (DDP,P) appear to
be active against gastric cancer (Wils & Bleiberg, 1989;
Lacave et al., 1983). The combinations of the most widely
used single agents are the FAM, the FAP, the EAP and the
5FU/DDP regimens. Response rates of these combinations
range between 22% and 40% with a median survival time
between 6 and 12 months. Some cases of documented com-
plete response have been reported with the FAP and the EAP
(Wils & Bleiberg, 1989; Preusser et al., 1989). The combina-
tion FAMTX (sequential high-dose methotrexate (MTX) and
5-fluorouracil combined with doxorubicin) has been studied
by the European Organization for Research and Treatment
of Cancer. A response rate of 33% was obtained with a
median survival of 6 months (Wils et al., 1986). In a subse-
quent study randomising FAM v FAMTX, a response rate of
42% was confirmed for the FAMTX with a median survival
of'42 weeks compared to 9% and 29 weeks for FAM (Wils et
al., 1991).
Twenty-four randomised clinical trials focusing on the
adjuvant treatment of gastric cancer published in English-
language periodical literature since 1965 are analysed. Seven-
teen are European or American (Tables I, II, III, IV) seven
are Japanese (Table V). Most of the trials are evaluating
chemotherapeutic or immuno-chemotherapeutic treatments.
Two of them report on the possible anti-tumour effect of the
histamine-2-receptor antagonist cimetidine and of the anti-
oestrogen tamoxifen.
Many- factors may interfere with the interpretation of the
data:
(a) The number of patients included in the trials is generally
small. Six trials out of 24 included less than 100 patients, 13
less than 200. Moreover seven trials had more than two
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Table I Adjuvant treatment ofgastric cancer: European and American studies (1)
Median
Nwnber % survivall survival
Authors (year) randomised Treatment no years (months) P
Serlin (1969) 190 surgery alone 32.2/3.5 15 n.s
110 FUdR (2 courses) 34.2/3.5 19
Huguier (1980) 26 surgery alone 18/5 27 n.s
27 5FU/VBL/CPM 16/5 24
(6 consecutive weeks)
Blake (1981) 34 surgery alone 12/5 15 n.s
29 CPM/MTX/5FU/VCR 10/5 15
(6 months)
Alcobendas (1982) 37 surgery alone 30/5 12 0.001
33 MMC 80/5 not reached
(4 courses, 24 weeks)
GITSG (1982) 71 surgery alone 31/5 33 0.003
71 5FU/MeCCNU 44/5 not reached
(2 years)
FUdR = 5-fluor-2'-deoxyuridine; 5FU = 5-fluorouracile; VBL = vinblastine; CPM = cyclophospha-
mide; MTX = methotrexate; VCR = vincristine; MMC = mitomycine C; MeCCNU = semustine.
Table II Adjuvant treatment ofgastric cancer: European and American studies (2)
Median
Number % survival/ survival
Authors (year) randomised Treatment no years (months) P
Higgins (1983) 68 surgery alone 77/3 26.5 n.s
66 5FU/MeCCNU 77/3 26.5
(1 year)
Engstrom (1985) 89 surgery alone 57/2 32.7 n.s
91 5FU/MeCCNU 57/2 36.6
(2 years)
Schlag (1987) 54 surgery alone 42/5 35 n.s
49 5FU/BCNU 57/5 not reached
(48-64 weeks)
Popiela (1988) 27 surgery alone NA NA
21 BCG + 5FU subset analysis subset analysis
9 5FU only only
5FU = 5-fluorouracile; MeCCNU = semustine; BCNU = carmustine; BCG = Bacille Calmette Guerin;
NA = not available.
Table III Adjuvant treatment of gastric cancer: European and American studies (3)
Median
Number % survival/ survival
Authors (year) randomised Treatment noyears (months) P
IGTSG (1988) 69 surgery alone
75 5FU/MeCCNU
69 5FU/MeCCNU 50/5 not reached n.s
/Levamisole
(80 weeks)
Allum (1989c) 130 surgery alone
140 SFU/VCR/MTX/CPM + 19/5 15.5 n.s
5FU/MMC (2 years)
141 5FU/MMC (2 years) 12/5
Allum (1989b) 145 surgery alone 8.9/5 14
138 surgery + FAM 5.8/5 18 n.s
153 surgery + RT 13/5 12
Lise (1989) 109 surgery alone overall overall NA
112 FAM (1 year) 36/3.5 42
Coombes (1990) 148 surgery alone 35.4/5 39 n.s
133 FAM (1 year) 45.7/5 51
Clark (1990) 21 surgery alone NA NA NA
9 FAMe
22 FMe (18 months)
5FU = 5-fluorouracile; MeCCNU = semustine; FAM = 5-fluorouracile, doxorubicin, mitomycin C;
RT = radiotherapy; FAMe = 5-fluorouracile, doxorubicin, semustine; FMe = 5-fluorouracile, semustine;
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Table IV Adjuvant treatment of gastric cancer: non-chemotherapy treatments
Median
Number % survivall survival
Authors (year) randomised Treatment no years (months) P
Tonnesen (1988) 75 surgery alone 0/5 10
82 Cimetidine 2/5 15 0.02
(two years)
47 surgery alone 30/2 10 n.s
Harrison (1989) 48 Tamoxifen 28/2 6.5 (as long as possible)
Table V Adjuvant treatment of gastric cancer: Japanese studies
Median
Number % survivall survival
Authors (year) randomised Treatment no years (months) P
Nakajima (1978) 223 surgery alone 43.5/5 NA n.s
207 MMC 52.5/5
(5 weeks)
Nakajima (1980) 38 surgery alone 56.0/5 not reached
42 MMC 64.3/5 not reached n.s
40 MMC/5FU/ARAC 66.9/5 not reached 0.05
(5 weeks)
Ochiai (1983) 40 surgery alone 31/5 13
49 SFU/MMC/ARAC + Tegafur 36/5 22
49 idem + BCG 18/5 46 0.05
(10 weeks, Tegafur as long as
possible)
Nakajima (1984) 79 surgery alone 51.4/5 not reached
81 MMC/5FU/ARAC + SFU po 68.4/5 not reached n.s
(2 years)
83 MMC/SFU/ARAC + Tegafur po 62.5/5 not reached
(2 years)
Koyama (1986) 98 Tegafur 60.2/5 not reached
115 Tegafur + N-CWS 73.2/5 not reached 0.002
(as long as possible)
Youn (1990) 120 SFU + ADM 59/4.5 not reached
129 5FU + poly(A) poly(U) 83/4.5 not reached 0.03
(as long as possible)
Maehara (1991) 118 surgery alone 45.7/15 96
137 MMC/SFU/PSK 56.9/15 not reached 0.03
(as long as possible)
MMC = mitomycin, SFU = 5-fluorouracile; ARAC = cytosine arabinoside; BCG = Bacille Calmette Guerin;
N-CWS = Nocardia rubracellwall skeleton; ADM = doxorubicin; poly(A) poly(V) = polyadenilicpolyuridilic acid;
PSK = krestin; po = orally; NA = not available.
randomisation arms. The size of these trials would never
allow a small difference in survival to be detected.
(b) The prognostic value of various characteristics related to
the patient (age, performance status) or to the tumour
(localisation, type of gastrectomy, penetration, lymph node
status, residual tumour, grade) is now well established. An
imbalance of these factors across treatment groups leads to
erroneous conclusions. For example, in a study comparing
different modalities combining radiotherapy and 5-FU, the
factorial design allowed comparison between patients who
received long term 5-fluorouracil (LT-5FU) to those who did
not. The advantage of LT-5FU was significant at P = 0.03
and the median survival of patients on the LT-5FU was 16
months compared to 10 months for the other patients.
Unfortunately an imbalance of prognostic factors between
the treatment groups, although not apparent, mandated
results comparisons be adjusted, which caused the advantage
of LT-5FU to disappear (Bleiberg, 1989).
In the reviewed papers important prognostic factors are
not considered, like localisation of the primary tumour
(Allum et al., 1989a; 1989b; Harrisson et al., 1989; Nakajima
et al., 1978; Koyama et al., 1986; Ochiai et al., 1983; Popiela
et al., 1988; Allum et al., 1989c; GITSG, 1982), age
(Coombes et al., 1990; Harrisson et al., 1989), and perform-
ance status or loss of weight (Higgins et al., 1983; Alcoben-
das et al., 1983; Coombes et al., 1990; Harrison et al., 1989;
Tonnesen et al., 1988; Moertel et al., 1984; Hugier et al.,
1980; Nakajima et al., 1980; Koyama et al., 1986; Maehara
et al., 1990; Ochiai et al., 1983; Schlag, 1987; IGTSG, 1988).
Only two trials seem to have looked at all known prognostic
factors: a Japanese one (Nakajima et al., 1984) that shows no
effect of treatment on survival, and an American one
(GITSG, 1982) that demonstrates a benefit in survival for the
treatment arm. Few trials performed a multivariate analysis
of prognostic factors and none gave a definition of risk by
treatment arm (Byar, 1982).
(c) An inadequate staging within the treatment groups,
underevaluating the number of involved lymph nodes or
ignoring patients with residual disease could mask the poten-
tial benefit of the treatment. Since the accuracy of staging
may vary with the extent of surgical procedure, surgery
should be standardised and a central review of pathology
should be organised.
The report on surgery varies among the papers. The
majority of them gives no details on the procedure (Harris-
son et al., 1989; Tonnesen et al., 1988; Moertel et al., 1984;
Engstrom et al., 1985; Hugier et al., 1980; Nakajima et al.,
1978; Nakajima et al., 1980; Maehara et al., 1990; Schlag,
1987; Lise et al., 1989; Allum et al., 1989c; Koyama et al.,
1986; Higgins et al., 1983; Popiela et al., 1988; GITSG, 1982;
Blake et al., 1981; Alcobendas et al., 1983) some lay down
guidelines for surgical procedure (Coombes et al., 1990;990 H. BLEIBERG et al.
Ochiai et al., 1983; Serlin et al., 1969; GITSG, 1982; IGTSG,
1988) or recommend a specific type of resection (Allum et al.,
1989b). None had organised a pathological review of all
operative specimens (Coombes et al., 1990).
The confusion regarding interpretation of the data may
even be greater when patients are not stratified according to
whether they had curative surgery or not (Allum et al.,
1989b; Blake et al., 1981; Ochiai et al., 1983; Serlin et al.,
1969).
With all these restrictions in mind, what are the responses
to treatment? Out of 24 studies, one has no data available on
survival (Lise et al., 1989), 11 are negative, six are positive,
and six present positive results of treatment in subset groups
of patients defined a posteriori but are negative when the
entire group is analysed.
Among the six trials showing a benefit on survival in
favour of the investigational treatment, two were testing
chemotherapy agents (Alcobendas et al., 1983; GITSG,
1982), three immunotherapy (Ochiai et al., 1983; Koyama et
al., 1986; Youn et al., 1989) and one the histamine-2-receptor
antagonist cimetidine.
Chemotherapy consisted of Mitomycin C (Alcobendas et
al., 1983) and 5FU/MeCCNU (GITSG, 1982). Mitomycin C
was given at the dose of 20 mg m-2 every 6 weeks for four
consecutive cycles. The 5-year survival was 30% for surgery
alone compared to 80% for MMC treated patients. The
effect of treatment is still evident after 10 years of follow-up
(Estape et al., 1991). The treatment was well tolerated and
toxicity was only acute and mild. MMC was also evaluated
at the dose of 0.08 mgkg-' twice a week for 5 consecutive
weeks (Nakajima et al., 1984). In that trial, there was no
benefit on survival. 5FU/MeCCNU was given during 2 years
(GITSG, 1982). The 5-year survival rate was 31% for surgery
alone compared to 44% for chemotherapy treated patients.
Forty-five per cent of the patients had severe hematological
toxicities and 8.4% a severe episode of gastrointestinal symp-
toms. A similar schedule was evaluated in two other trials
which did not confirm the results of the GITSG (Higgins et
al., 1983; Engstrom et al., 1985).
Immunotherapy consisted of cell wall skeleton of Bacillus
Calmette-Guerin (BCG-CWS), combined to 5FU/MMC/
ARAC + tegafur as long as possible (Ochiai et al., 1983), of
Nocardia rubra cell wall skeleton (N-CWS), combined to
tegafur as long as possible or of polyadenylic-polyuridilic
acid (Poly(A)-poly(U)) combined to 5FU and doxorubicin as
long as possible. Immunotherapy is compared to chemo-
immunotherapy. The trial of Ochiai had also a control arm
without further treatment after surgery. In the BCG-CWS
trial (Ochiai et al., 1983), the 5-year survival rates are 31%,
18% and 36% respectively for surgery alone, chemotherapy
and chemo-immunotherapy. In the N-CWS trial (Koyama et
al., 1986), the 5-year survival rates are 60.2% and 73.2%
respectively for chemotherapy and chemo-immunotherapy. In
poly(A)-poly(U) the 5-year survival rates are 59% and 83%
respectively for chemotherapy and chemo-immunotherapy.
Several reports have indicated a possible antitumour effect
of the histamine-2-receptor antagonist cimetidine in mouse
and in man (Osband et al., 1981). Cimetidine may also
enhance immune function. Patients treated with cimetidine
for 2 years have a median survival time of 15 months com-
pared to 10 months for patients treated by surgery alone
(P = 0.02) (Tonnesen et al., 1988).
Our review of the randomised controlled trials with
chemotherapy and chemo-immunotherapy is disappointing.
Only six trials demonstrate a significant prolongation of sur-
vival with the treatment investigated. However, in all other
trials, there is a trend in favour of the investigational treat-
ment.
The analysis of these past trials may help designing new
studies. The activity of MMC, immunochemotherapy and
cimetidine is worth being confirmed but new promising com-
binations like FAMTX should also be further investigated.
The new trials should be randomised and include a control
arm with surgery as sole therapy. They should be large
enough to identify small differences in survival. Surgery
should be standardised, and risk groups defined a priori.
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